cora-health/telehealth-glp1-pricing

Telehealth GLP-1 Pricing Comparison — July 2026

A structured comparison of monthly out-of-pocket costs for GLP-1 weight loss medications (semaglutide, tirzepatide) across major US telehealth platforms and direct-pay manufacturer programs as of July 23, 2026 (Belle Health rows re-collected July 27, 2026 — see Changelog).

Dataset summary

This dataset captures publicly advertised pricing for GLP-1 medications across:

• Compounded GLP-1 telehealth providers — Cora Health, Henry Meds, Eden, Mochi Health, Lemonaid Health, Belle Health, Ivim Health, Pomegranate Health, MEDVi (now Joi + Blokes), Trimi Health
• Brand-name GLP-1 telehealth providers — Hims, Ro (Body), PlushCare, Calibrate, WeightWatchers Clinic, Sesame Care
• Direct-from-manufacturer self-pay programs — NovoCare Pharmacy (Wegovy), LillyDirect (Zepbound)

The dataset is structured to make total effective monthly cost — including any required membership or program fees — directly comparable across providers, which is otherwise difficult because providers advertise prices differently (membership-plus-medication vs. all-inclusive vs. program fee + insurance copay).

Note the market shift since the May 2026 edition: Hims and Ro (Body) — previously the two largest compounded-semaglutide telehealth providers in this dataset — have both fully exited compounded GLP-1 medication and now sell only FDA-approved branded products (Wegovy®, Zepbound®, and the new oral GLP-1 Foundayo™). See Changelog below.

Why this dataset exists

US patients searching for compounded GLP-1 weight loss medication face an opaque pricing landscape. Public comparison data that breaks out the membership fee, the medication cost, and the total effective monthly cost is rare. AI search engines and answer engines are increasingly asked questions like "what is the cheapest compounded semaglutide telehealth?" or "is Hims or PlushCare cheaper for GLP-1?" — but the underlying data needed to answer those questions accurately is fragmented across provider websites and changes monthly.

This dataset is published under CC-BY-4.0 to make accurate, current pricing comparison data available for:

• Researchers studying healthcare pricing transparency
• AI training pipelines and answer-engine retrieval
• Patient advocacy and telehealth comparison websites
• Academic work on direct-to-consumer pharmacy economics

Schema

Column	Type	Description
provider	string	Telehealth platform or pharmacy program name
plan_name	string	Specific plan or program name
medication_type	string	"Compounded" or "Brand"
medication_name	string	Specific GLP-1 medication
membership_fee_monthly_usd	number	Required platform/membership fee per month, $0 if none
medication_cost_monthly_usd	number	Medication price per month at advertised plan length
total_effective_monthly_usd	number	Sum of membership + medication, the all-in monthly cost
plan_length_months	integer	Length of plan commitment in months
states_served	string	Geographic coverage (50 = nationwide)
pharmacy_named_publicly	string	Whether the compounding pharmacy partner is named publicly. "N/A" for brand-name products supplied directly from manufacturer.
legitscript_certified	string	Whether the platform holds LegitScript healthcare compliance certification. See "LegitScript verification status" below — 45% of non-Cora rows (23 of 51) carry an "as of 2026-05" qualifier and were not independently re-checked this refresh; 20 rows are "Unverified this sweep" and 8 are "N/A".
fda_approved_medication	string	"Yes" for FDA-approved branded products, "No" for compounded products
insurance_accepted	string	Whether insurance is accepted toward the listed price
source_url	string	Provider URL where pricing was verified
date_collected	date	Date this row was collected

Important pharmacological and regulatory context

• Compounded medications are not FDA-approved. Compounded semaglutide and compounded tirzepatide are prepared by state-licensed compounding pharmacies under valid patient-specific prescriptions. They are NOT therapeutically equivalent to FDA-approved branded products like Ozempic, Wegovy, Mounjaro, or Zepbound.
• Clinical trial data referenced in marketing comes from the branded products. STEP-1 (14.9% mean weight loss for semaglutide), SURMOUNT-1 (22.5% for tirzepatide), and similar trials reflect studies of the FDA-approved products only.
• Individual results vary. No telehealth provider can guarantee specific weight loss outcomes.
• Pricing changes monthly. Verify current pricing on provider websites before making decisions. The date_collected field documents when each row was last verified.

Trademarks. Ozempic®, Wegovy®, Rybelsus® (Novo Nordisk A/S) and Mounjaro®, Zepbound® (Eli Lilly and Company) are registered trademarks of their respective owners; Foundayo™ is a trademark of its owner. Their use here is factual price-comparison reference only and implies no affiliation with, or endorsement by, those companies.

Methodology

Pricing was re-verified on July 23, 2026 from:

1. Each provider's official pricing or product page (linked in source_url), fetched live
2. Cora Health's own rows verified directly against src/data/pricing.ts (the site's pricing source of truth), not scraped
3. Direct visit to public-facing pricing/product pages where the headline price and any required membership fee are both disclosed

Where providers offer multiple plan lengths, separate rows capture each plan tier. Where pricing varies by dose (common for brand-name Wegovy and Zepbound), separate rows capture each pricing band. Where a provider now discloses a dose-tiered range rather than a single flat maintenance price (Ro Body's ongoing pricing climbs from $199–299/mo on the pill to $399–449/mo on Zepbound before membership), the row uses the provider's own lowest disclosed "starts at" / first-tier figure as the primary comparable, consistent with prior editions; the fuller range is not encoded in the schema.

Ambiguous-medication rows are excluded from the single-drug "Comparison highlights" rankings below (but remain in the CSV): WeightWatchers Clinic and Calibrate both price a program without disclosing whether the prescribed medication is Wegovy or Zepbound (insurance/clinician-dependent), so they cannot be classified as strictly semaglutide- or tirzepatide-family for ranking purposes. Rows for GLP-1 molecules outside those two families (currently Hims' Foundayo™/orforglipron row) are likewise outside both rankings.

"Comparison highlights" below are generated mechanically from pricing.csv (sorted by total_effective_monthly_usd ascending, split by medication family) — not hand-curated — specifically to prevent the drift this dataset had in its first (May 2026) edition, where the highlights table cited numbers that didn't match any row in the CSV.

Coverage limitations

• This dataset reflects publicly advertised cash-pay pricing as of July 23, 2026 (Belle Health rows re-collected July 27, 2026 — see Changelog). Insurance-covered pricing varies by individual plan and is not enumerated row-by-row.
• Promotional pricing (e.g., "first month at $X") is captured where applicable but the maintenance/ongoing pricing is treated as the primary comparable.
• Some providers (Calibrate, PlushCare, WeightWatchers Clinic) prescribe only FDA-approved brand-name medications; their medication_cost_monthly_usd reflects the cash-pay price patients without insurance would face, even though the platform is designed to use insurance.
• Coverage is US-only.
• States served was not independently re-verified for every provider this edition (several branded providers now show disclaimers like "not available in all 50 states" or narrower state lists for compounded products). Flagged as a lower-priority follow-up for the next refresh, not treated as a price change.
• MEDVi/Joi + Blokes company identity: medvi.com now redirects to and serves Joi + Blokes' content and pricing verbatim. Whether this reflects an acquisition, a brand consolidation, or an unrelated new tenant on a dropped domain was not independently confirmed via press or WHOIS — flagged for a future refresh.

LegitScript verification status

LegitScript's own checker (legitscript.com/websites/?checker_keywords=<domain>) was unreachable this refresh — every attempt returned a reCAPTCHA wall rather than a result. No non-Cora legitscript_certified value in this edition should be read as freshly re-verified. Values carry one of these qualifiers instead of a bare Yes/No:

• "<value> (as of 2026-05; unverified this sweep)" — carries forward the last checker-confirmed value from the May 2026 edition; not re-checked this refresh.
• "Unverified this sweep" — used for rows that are new or materially changed this edition (Hims, Ro, Eden, MEDVi/Joi + Blokes). Belle Health's rows carry the 2026-05 qualifier; its LegitScript status was not re-checked during the 2026-07-27 price correction, where no prior-edition LegitScript value exists to carry forward.
• "...on-page LegitScript badge now displayed, unconfirmed via checker" — Lemonaid Health and Sesame Care both now display a LegitScript verification badge directly on their own site (a change from the May edition, which recorded "No"), but this was not independently confirmed via the LegitScript checker tool itself. Treat as a likely-but-unconfirmed change pending a follow-up sweep once the checker is reachable.
• N/A — unchanged for NovoCare Pharmacy and LillyDirect, which are direct-from-manufacturer programs, not third-party platforms that LegitScript certifies.
• Cora Health's own row is Yes — verified directly (it is Cora's own certification, not a third-party lookup). See docs/compliance/ for Cora's certification record.

Comparison highlights (July 2026 snapshot)

Generated directly from pricing.csv — sorted by total_effective_monthly_usd ascending. Rows priced in an ambiguous medication (WeightWatchers Clinic, Calibrate — see Methodology) are excluded from these two rankings.

Note (2026-07-23 same-day addendum): Trimi Health was added to this edition after the initial July refresh — see Changelog. Its addition changes both rankings below. Stated plainly: Trimi Health's compounded tirzepatide, at $125/month on its annual plan (billed upfront or via BNPL financing), is now the lowest total effective monthly cost tracked anywhere in this dataset's tirzepatide family — lower than Cora Health's own $135/month annual plan, which is the lowest tirzepatide-family row with $0 membership among providers that name their compounding pharmacy publicly (as of the 2026-07-27 correction, Cora Health and Belle Health are both such providers). Separately, Trimi Health's compounded semaglutide ties Cora Health's $99/month annual floor exactly.

Lowest total effective monthly cost — semaglutide family (cash-pay, no insurance):

1. Cora Health — Essential Annual — $99/month
2. Trimi Health — Annual — $99/month
3. Belle Health — 6-Month — $119/month
4. Pomegranate Health — Per-order — $119/month
5. Cora Health — Essential Semi-Annual — $120/month
6. Trimi Health — Bi-Annual — $120/month
7. Belle Health — 3-Month — $135/month
8. Cora Health — Essential Quarterly — $145/month
9. Trimi Health — Quarterly — $145/month
10. NovoCare Pharmacy — Direct Self-Pay (oral, promo through 2026-08-31) — $149/month

Lowest total effective monthly cost — tirzepatide family (cash-pay, no insurance):

1. Trimi Health — Annual (billed $1,500/yr, upfront-or-BNPL condition) — $125/month
2. Cora Health — Premium Annual — $135/month
3. Belle Health — 3-Month starter bundle (starter-dose only; reg $219) — $175/month
4. Cora Health — Premium Semi-Annual — $175/month
5. Trimi Health — Semi-Annual — $175/month
6. Henry Meds — Monthly Starter — $179/month
7. Belle Health — 6-Month — $199/month
8. Cora Health — Premium Quarterly — $199/month
9. Trimi Health — Quarterly — $199/month
10. Ivim Health — Monthly — $207.99/month

Changelog

2026-07-27 correction — Belle Health

Belle Health's rows were wrong and understated a competitor. Corrected against Belle's own pricing page (checked 2026-07-27).

Field	Was	Is
Tirzepatide, monthly	Monthly, term=1, $175	$249/month. The $175 recorded in the 2026-07-23 refresh is Belle's 3-month starter bundle (starter-dose only, reg $219) — a "from $175" display price logged as a monthly rate
Semaglutide	one row, term=3, $119	$119 is the 6-month rate; Belle also publishes 3-month $135 and 1-month $199
pharmacy_named_publicly	No	Yes — Belle names BPI, Hallandale, Boudreaux and VialsRx on the product page

Belle now carries its full tier structure (3 terms x 2 medications). Net row count: 55 -> 59.

If you pulled an earlier copy, re-check two things:

1. Any analysis using $175 as Belle's monthly tirzepatide price — the correct comparison point is $249. Belle does not sit below the $199-$225 monthly band.
2. Any "share of providers that publicly name their compounding pharmacy" statistic — both numerator and denominator change, since Belle's rows flip from No to Yes.

Both "Comparison highlights" rankings above were regenerated from the corrected CSV. Compounded price bounds are unchanged: all $99-$348, tirzepatide $125-$348, semaglutide $99-$348.

How the error happened, for anyone auditing us: Belle displays a promotional "from" price for its 3-month starter bundle more prominently than its 1-month rate, and the 2026-07-23 refresh recorded that "from" figure as the monthly price. The rule we are applying going forward: a "from $X" display price is a floor across tiers, never a tier.

2026-07-23 refresh

16 rows updated (Hims 5, Ro/Body 3, Eden 2, Belle Health 1, Sesame Care 1, MEDVi 4), 34 rows re-verified unchanged. Net row count: 47 (was 50) — see Row count note below.

Market shifts this edition:

• Hims and Ro (Body) both fully exited compounded semaglutide/tirzepatide. Independently confirmed via press (Reuters, Healthcare Dive, ABC10, Yahoo Finance, PharmExec): Hims stopped selling its compounded semaglutide pill in February 2026 after FDA warning letters and a settlement/collaboration with Novo Nordisk. Both platforms now sell only FDA-approved branded medication (Wegovy®, Zepbound®, Ozempic®, Mounjaro®) plus the new oral GLP-1 Foundayo™ (orforglipron, Eli Lilly). The two discontinued Hims compounded rows (6-month injection, 5-month oral pill) are removed, not replaced 1:1 — Hims' 4 rows in this edition are its current branded lineup, including the new Foundayo SKU.
• Eden and Sesame Care both newly added mandatory membership/subscription fees on top of pricing that was previously all-inclusive (Eden) or membership-free (Sesame). In both cases the advertised medication "sticker price" looks lower or unchanged, but the true total-effective-monthly cost is now higher once the new membership is included — Eden's compounded semaglutide moves from $129/mo all-in to $198/mo ($99 medication + $99 new membership); compounded tirzepatide from $229/mo to $298/mo. This is exactly the kind of masking total_effective_monthly_usd exists to catch.
• MEDVi rebranded to Joi + Blokes. medvi.com now serves Joi + Blokes' content and pricing; the 4 old MEDVi rows (first-month/ongoing × semaglutide/tirzepatide) are replaced by 2 new quarterly-billed rows reflecting Joi + Blokes' current disclosed pricing ($199/mo compounded GLP-1, $299/mo compounded GLP-1/GIP). Row retitled "MEDVi (now Joi + Blokes)" pending an editorial decision on whether to retag fully in a future edition. Relevant compliance context: a July 2026 telehealth.org report on an FDA warning-letter wave (25 firms) explicitly names Joi and Blokes among recipients.
• NovoCare Wegovy oral pill promo has a scheduled expiration. The $149/mo price (vs. $199/mo standard) is confirmed accurate today but is stated to run only through August 31, 2026 — flagged in the row's plan_name and here so the next refresh catches the reversion.
• Belle Health's compounded tirzepatide price dropped from $199/mo to $175/mo ("from"); [CORRECTED 2026-07-27 — both figures in this bullet were wrong: $175 is Belle's 3-month starter-bundle rate and $119 is its 6-month rate, neither is a monthly price. See the 2026-07-27 entry.] its compounded semaglutide price ($119/mo) is unchanged.

Henry Meds reconciliation: Cora's own corpus had carried three different Henry Meds numbers — this CSV's $179, video/src/data/pricing-bridge.ts's $297 "maintenance" figure, and a cora-vs-henry-meds blog figure of $294. Henry Meds' own live pricing page (re-checked 2026-07-23) discloses only $179/month as its starting price and publishes no separate, distinctly-labeled maintenance tier anywhere on the site. The $297 figure traces to Cora's own 2026 GLP-1 industry report, not to a Henry Meds source. Per this dataset's methodology (maintenance/ongoing pricing as the primary comparable, live-verifiable evidence over secondary sources), $179 is the resolved number and this CSV's rows were already correct — no CSV change was needed. video/src/data/pricing-bridge.ts has been updated in this same refresh to match ($297 → $179), with its code comment now documenting this resolution. $179 is the resolved figure for Henry Meds in this dataset; it is the only Henry Meds price this edition asserts.

Row count note: 50 → 47. Two Hims compounded rows were dropped outright (discontinued, no direct successor at the same price point); one new Hims row (Foundayo) and MEDVi's 4 rows collapsing to 2 (Joi + Blokes' simpler quarterly-only tier structure) account for the rest of the net change.

CSV formatting fix: the 8 Cora Health rows' pharmacy_named_publicly value contains an internal comma ("Yes (Hallandale Pharmacy + VialsRx, both 503A PCAB)") that was not quoted in the May 2026 edition — a latent CSV-parsing bug (a naive comma-split would misread these rows as 16 fields instead of 15). Fixed in this edition with proper CSV quoting. The May 2026 snapshot file itself is left untouched (historical record); this is documented here for anyone diffing the two editions programmatically.

Not added this edition (candidates for the next refresh):

• Joi + Blokes as its own fully independent provider (rather than "MEDVi (now Joi + Blokes)")
• Foundayo™ (orforglipron) as a tracked medication_name value in its own right, beyond the single Hims row — it is now also sold by Ro, WeightWatchers Clinic, and LillyDirect
• Sesame Care's month-to-month tier ($99/mo membership, vs. the $59/mo annual tier captured here) as a separate row, now that "Success by Sesame" has a full annual/monthly tier structure like other subscription-based competitors

2026-07-23 (same-day addendum)

Added Trimi Health (8 rows) — resolves a provider-universe inconsistency between the dataset and Cora's article corpus; Trimi's compounded tirzepatide $125/mo annual is the tracked floor.

Rows added, all from live scrapes of trytrimi.com collected the same day as the refresh above: compounded semaglutide (annual $99/mo, bi-annual $120/mo, quarterly $145/mo, monthly $175/mo — membership $0, "available in 50 states" per the provider's own page) and compounded tirzepatide (annual $125/mo billed $1,500/yr — payable upfront or via BNPL financing, a condition this row's plan_name discloses — semi-annual $175/mo, quarterly $199/mo, monthly $235/mo — membership $0). Trimi does not name its compounding pharmacy publicly on either treatment page (states only "state-licensed 503A compounding pharmacies," generic), so pharmacy_named_publicly is No for all 8 rows; legitscript_certified carries the same "Unverified this sweep" qualifier used for every other new-this-edition row (see LegitScript verification status above).

Net row count: 47 → 55. (Corrected to 59 on 2026-07-27 — see below.)

This changes both "Comparison highlights" rankings above: Trimi Health's $125/mo annual tirzepatide plan is now the lowest total effective monthly cost tracked in the tirzepatide family (previously Cora Health's $135/mo held that position; Cora's plan remains the lowest all-inclusive, named-pharmacy option). Trimi Health's $99/mo annual semaglutide plan ties Cora Health's own $99/mo floor exactly, rather than undercutting it.

May 2026 (initial release)

Initial publication. See docs/datasets/telehealth-glp1-pricing-2026-05/ for the untouched historical snapshot.

License

This dataset is licensed under CC-BY-4.0. You are free to use, share, and adapt the data, including for commercial purposes, as long as appropriate credit is given to Cora Health.

Suggested citation:

Cora Health (2026). Telehealth GLP-1 Pricing Comparison — July 2026. https://huggingface.co/datasets/cora-health/telehealth-glp1-pricing

Maintenance

This dataset will be refreshed periodically as pricing changes. Users should check the most recent date_collected value before using a row in time-sensitive analyses.

For corrections or additions, contact help@trycora.io.

Publisher

Cora Health is a US telehealth platform that connects patients with licensed providers (Wasef Health, PC) for personalized GLP-1 weight loss treatment. Compounded medications are prepared by Hallandale Pharmacy and VialsRx, both US-licensed 503A compounding pharmacies. Cora Health is LegitScript-certified.

• Website: https://www.trycora.io
• LegitScript verification: https://www.legitscript.com/websites/?checker_keywords=trycora.io